Gene expressions involved in immune system control and serum CA125 content in polycythemia vera. Tap
Keywords:Anti-aging function, blood cancer, immune checkpoints, polycythemia vera.
Polycythemia Vera (PV) is a slowly progressing blood cancer associated with myeloproliferative neoplasms. The disease is characterized by an abnormal proliferation of three cell types including red blood cells, white blood cells and platelets and a symptom of pruritus caused by release of itching agents of activated mast cells. The enhanced expression of several genes involved in immune system control including CTLA-4, PD-1 and LAG3 are linked to activation immune tolerance. Klotho gene has anti-aging, anti-inflammation and anti-cancer functions. The SHP gene group belongs to the tyrosine phosphatase protein signaling family that regulates cancer cell proliferation through maturation, migration and apoptosis and includes two main genes, SHP-1 and SHP-2. The increased serum content of cancer antigen CA125 is considered as a cancer marker of several blood and hematopoietic disorders. In this study, we conducted experiments to determine mRNA expression of above genes in PV patients by realtime-PCR and CA125 concentration by ELISA. Results showed that expression of klotho, LAG3, CTLA-4 and PD-1 genes was decreased in PV patients, indicating that the immune tolerance was inactivated in PV patients. CA125 concentration was significantly increased in PV patients compared to healthy individuals and interestingly, there was a positive association among three patients, who having increased CA125 concentration and biochemical indicators including LDH, AST and ALT. The results in this study provide an important reference document for further studies that serve for the early detection of PV disease.
Afrin L. B., 2011. Polycythemia from mast cell activation syndrome: lessons learned. Am. J. Med Sci., 342: 44−49.
Birgen D., Ertem U., Duru F. et al., 2005. Serum Ca 125 levels in children with acute leukemia and lymphoma. Leuk Lymphoma, 46: 1177−1181.
Buchbinder E., & Desai A., 2015. CTLA-4 and PD-1 Pathways: Similarities, Differences, and Implications of Their Inhibition. American journal of clinical oncology 39:
Chan R. J., Li Y., Hass M. N. et al., 2006. Shp-2 heterozygous hematopoietic stem cells have deficient repopulating ability due to diminished self-renewal. Exp. Hematol., 34: 1230−1239.
Chim C. S., Fung T. K., Cheung W. C., Liang R., & Kwong Y. L., 2004. SOCS1 and SHP1 hypermethylation in multiple myeloma: implications for epigenetic activation of the Jak/STAT pathway. Blood, 103: 4630−4635.
Dance M., Montagner A., Salles J. P., Yart A., & Raynal P., 2008. The molecular functions of Shp2 in the Ras/Mitogen-activated protein kinase (ERK1/2) pathway. Cell Signal., 20: 453−459.
Gungor T., Kanat-Pektas M., Sucak A., & Mollamahmutoglu L., 2009. The role of thrombocytosis in prognostic evaluation of epithelial ovarian tumors. Arch Gynecol Obstet, 279: 53−56.
Hantschel O., Warsch W., Eckelhart E. et al., 2012. BCR-ABL uncouples canonical JAK2-STAT5 signaling in chronic myeloid leukemia. Nature chemical biology, 8: 285−293.
Hehlmann R., Hochhaus A., Baccarani M., & European L., 2007 Chronic myeloid leukaemia. Lancet, 370: 342−350.
Kitamura T., Qian B. Z., & Pollard J. W., 2015. Immune cell promotion of metastasis. Nat. Rev. Immunol., 15: 73−86.
Kuro-o M., 2009. Klotho and aging. Biochim Biophys Acta, 1790: 1049−1058.
Liang B., Workman C., Lee J. et al., 2008. Regulatory T cells inhibit dendritic cells by lymphocyte activation gene-3 engagement of MHC class II. J. Immunol., 180: 5916−5926.
Liu X., & Qu C. K., 2011. Protein Tyrosine Phosphatase SHP-2 (PTPN11) in Hematopoiesis and Leukemogenesis. J Signal Transduct, 2011: 195239.
Lorenz U., 2009. SHP-1 and SHP-2 in T cells: two phosphatases functioning at many levels. Immunol Rev., 228: 342−359.
Markiewicz M., Panneerselvam K., & Marks N., 2016. Role of Klotho in migration and proliferation of human dermal microvascular endothelial cells. Microvasc Res., 107: 76−82.
Misawa K., Yasuda H., Araki M. et al., 2018. Mutational subtypes of JAK2 and CALR correlate with different clinical features in Japanese patients with myeloproliferative neoplasms. Int. J. Hematol., 107: 673−680.
O’Brien T., Beard J., Underwood L. et al., 2001. The CA 125 Gene: An Extracellular Superstructure Dominated by Repeat Sequences. Tumour biology: the journal of the International Society for Oncodevelopmental Biology and Medicine, 22: 348−366.
Oka T., Ouchida M., Koyama M. et al., 2002. Gene silencing of the tyrosine phosphatase SHP1 gene by aberrant methylation in leukemias/lymphomas. Cancer Res., 62: 6390−6394.
Rota G., Niogret C., Dang A. T. et al., 2018. Shp-2 Is Dispensable for Establishing T Cell Exhaustion and for PD-1 Signaling In Vivo. Cell Rep., 23: 39−49.
Siegel F. P., Tauscher J., & Petrides P. E., 2013. Aquagenic pruritus in polycythemia vera: characteristics and influence on quality of life in 441 patients. Am. J. Hematol., 88: 665−669.
Tajan M., de Rocca Serra A., Valet P., Edouard T., & Yart A., 2015. SHP2 sails from physiology to pathology. Eur. J. Med Genet, 58: 509−525.
Wickrema A., Chen F., Namin F. et al., 1999. Defective expression of the SHP-1 phosphatase in polycythemia vera. Exp Hematol., 27: 1124−1132.
Wu J. Z., Tian T., Huang Y. et al., 2016. Serum carbohydrate antigen 125 concentration as a superior predictor for serosal effusion at diagnosis and a prognostic factor in diffuse large B-cell lymphoma. Cancer Biomark, 17: 205−212.
Yang J.-J., Chen H., Zheng X.-Q. et al., 2015. Methylated Alteration of SHP1 Complements Mutation of JAK2 Tyrosine Kinase in Patients with Myeloproliferative Neoplasm. Asian Pacific journal of cancer prevention: APJCP, 16: 2219−2225.